Literature DB >> 12209080

Smallpox vaccination: Risk considerations for patients with atopic dermatitis.

Renata J M Engler1, Julie Kenner, Donald Y M Leung.   

Abstract

As the threat of bioterrorism with pathogenic microbes such as smallpox virus (Variola major) increases, the question of widespread voluntary vaccination with smallpox (vaccinia) vaccines is being carefully considered. A major challenge lies in the ability to protect the population from the disease while minimizing the considerable side effects from the vaccine. Individuals with active or quiescent atopic dermatitis are at increased risk for vaccinia complications. The nature of these complications and other considerations are summarized in this rostrum.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209080     DOI: 10.1067/mai.2002.128052

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  38 in total

1.  Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status.

Authors:  Joanne Domenico; Joseph J Lucas; Mayumi Fujita; Erwin W Gelfand
Journal:  Int Arch Allergy Immunol       Date:  2012-01-26       Impact factor: 2.749

2.  Bioterrorism and smallpox planning: information and voluntary vaccination.

Authors:  M J Selgelid
Journal:  J Med Ethics       Date:  2004-12       Impact factor: 2.903

3.  Long-term safety of replication-defective smallpox vaccine (MVA-BN) in atopic eczema and allergic rhinitis.

Authors:  U Darsow; M Sbornik; S Rombold; K Katzer; F von Sonnenburg; H Behrendt; J Ring
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-06-29       Impact factor: 6.166

4.  Diversity in the acute CD8 T cell response to vaccinia virus in humans.

Authors:  Lichen Jing; Tiana M Chong; Christopher L McClurkan; Jay Huang; Brian T Story; David M Koelle
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

5.  Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.

Authors:  Christine Pugh; Sarah Keasey; Lawrence Korman; Phillip R Pittman; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2014-04-23

6.  Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.

Authors:  Marina Zaitseva; Kevin Tyler McCullough; Stephanie Cruz; Antonia Thomas; Claudia G Diaz; Laurie Keilholz; Irma M Grossi; Lawrence C Trost; Hana Golding
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

7.  IL-10 suppresses IL-17-mediated dermal inflammation and reduces the systemic burden of Vaccinia virus in a mouse model of eczema vaccinatum.

Authors:  Alanna R Darling; Eva-Jasmin Freyschmidt; Oliver T Burton; Kyle J Koleoglou; Michiko K Oyoshi; Hans C Oettgen
Journal:  Clin Immunol       Date:  2013-11-27       Impact factor: 3.969

8.  Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis.

Authors:  Madison R Mack; Jonathan R Brestoff; Melissa M Berrien-Elliott; Anna M Trier; Ting-Lin B Yang; Matthew McCullen; Patrick L Collins; Haixia Niu; Nancy D Bodet; Julia A Wagner; Eugene Park; Amy Z Xu; Fang Wang; Rebecca Chibnall; M Laurin Council; Carrie Heffington; Friederike Kreisel; David J Margolis; David Sheinbein; Paola Lovato; Eric Vivier; Marina Cella; Marco Colonna; Wayne M Yokoyama; Eugene M Oltz; Todd A Fehniger; Brian S Kim
Journal:  Sci Transl Med       Date:  2020-02-26       Impact factor: 17.956

9.  Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis.

Authors:  Emma Guttman-Yassky; Michelle A Lowes; Judilyn Fuentes-Duculan; Lisa C Zaba; Irma Cardinale; Kristine E Nograles; Artemis Khatcherian; Inna Novitskaya; John A Carucci; Reuven Bergman; James G Krueger
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum.

Authors:  Yuko Kawakami; Yoshiaki Tomimori; Kenji Yumoto; Shunji Hasegawa; Tomoaki Ando; Yutaka Tagaya; Shane Crotty; Toshiaki Kawakami
Journal:  J Exp Med       Date:  2009-05-25       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.